Clene Inc. Form 8-K Summary
Business Context and Reporting Period
Clene Inc. (CLNN), a biopharmaceutical company based in Salt Lake City, Utah, filed this Current Report on Form 8-K on September 15, 2026. The filing details the entry into a material definitive agreement to raise capital through a private placement of common stock.
Key Financial Metrics
- Capital Raised: Approximately $4.0 million in aggregate gross proceeds.
- Shares Issued: 1,219,513 shares of common stock.
- Offering Price: $3.28 per share.
- Transaction Costs: No underwriting discounts or commissions; offering expenses are described as insignificant.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for current period revenue, profit, cash flow, margins, or debt levels.
Material Changes
The primary material change is the execution of a Securities Purchase Agreement with certain existing stockholders, including directors and officers. The transaction is expected to close on September 17, 2026. This represents a dilution of existing shareholders but provides immediate liquidity to the company.
Outlook, Management Commentary, and Risks
Use of Proceeds: Net proceeds will be used for general corporate purposes, specifically to fund:
- Regulatory dialogue and preparation of regulatory filings.
- Preparation of a New Drug Application (NDA) for the lead drug candidate, CNM-Au8.
- Expanded access protocols.
- Potential future commercialization efforts and manufacturing expansion.
Risks and Contingencies: The company relies on the successful progression of CNM-Au8 through regulatory channels. The filing notes that the Securities Purchase Agreement contains customary representations, warranties, and indemnification obligations.
Key Facts for Investor Verification
- Verify the closing date of September 17, 2026, and the actual receipt of the $4.0 million proceeds.
- Confirm the updated share count and dilution impact on existing shareholders post-closing.
- Monitor the timeline for the New Drug Application (NDA) filing for CNM-Au8 as the primary use of funds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.